Explorer

Covid: India's First Omicron-Specific Booster Vaccine Gets Drug Controller Nod

GEMCOVAC-OM is an mRNA-based booster vaccine aimed at the Omicron variant of Covid-19.

The Drug Control General of India (DCGI) has granted emergency use authorisation (EUA) to an Omicron-specific booster vaccine developed by Gennova Biopharmaceuticals Ltd. The vaccine has been developed by Gennova Biopharmaceuticals in collaboration with the Department of Biotechnology (DBT) under the 'Mission COVID Suraksha'.

The mRNA-based vaccine, GEMCOVAC-OM, was developed using the indigenous platform technology. It can be administered as a booster in participants who have received two doses of Covishield and Covaxin.

GEMCOVAC-OM is a thermostable vaccine, meaning that it does not require ultra-cold chain infrastructure used for other approved mRNA-based vaccines, making it easy for deployment across India.

READ | Consuming Diabetes Medicine Metformin After SARS-CoV-2 Infection Reduces Long Covid Risk By 40%: Study In Lancet

The vaccine is delivered intra-dermally using a needle-free injection device system instead of traditional syringes, eliminating the fear and anxiety associated with needles.

"When administered intradermally in participants as a booster, it generated significantly higher immune responses. The clinical outcome demonstrates the need for variant-specific vaccines for desired immune response," the government said in a press release.

Speaking on GEMCOVAC-OM getting DCGI nod, Jitendra Singh, Minister of Science and Technology, said, "I take great pride in DBT fulfilling its mission yet again -- enabling technology-driven entrepreneurship through creating this indigenous mRNA-platform technology. We have always supported technology-driven innovation towards the creation of a 'future-ready' technology platform in line with the Prime Minister's vision of Aatmanirbharta."

"Infrastructure to deploy vaccine in India, including LMICs, at 2‑8°C exist today and this innovation is tailored for the existing established supply-chain Infrastructure. The vaccine does not need ultra-low temperature conditions for transport and storage," he further said.

Rajesh S Gokhale, secretary, DBT, said GEMCOVAC-OM was developed using the mRNA-based disease agnostic platform technology that can be used to make other vaccines in a relatively short development timeline.

The clinical trial results of the vaccine found it to be safe and well tolerated and no vaccine-related serious adverse events were observed.

Check out below Health Tools-
Calculate Your Body Mass Index ( BMI )

Calculate The Age Through Age Calculator

View More
Advertisement
Advertisement
Wed Feb 26, 5:09 am
connaught place
20.8°
Precipitation: 0 mm    Humidity: 70%   Wind: S 4.3 km/h
See Today's Weather
Powered By:
Accu Weather
Advertisement

Top Headlines

Revanth Reddy Govt Issues Order To Make Telugu Compulsory In All Telangana Schools
Revanth Reddy Govt Order Makes Telugu Mandatory In All Telangana Schools
Devotees Throng Triveni Sangam For Maha Kumbh's Final 'Snan' On Maha Shivratri
Devotees Throng Triveni Sangam For Maha Kumbh's Final 'Snan' On Maha Shivratri
Shivling Stolen From Centuries-Old Dwarka Temple On Maha Shivratri Eve, Scuba Divers Deployed
Shivling Stolen From Centuries-Old Dwarka Temple On Shivratri Eve, Scuba Divers Deployed
From Bollywood To Industrialists: VIPs Who Took The Sacred Dip At Maha Kumbh 2025
From Bollywood To Industrialists: VIPs Who Took The Sacred Dip At Maha Kumbh 2025
Advertisement
ABP Premium

Videos

Maha Shivratri: Naga Sadhus Gather on the Streets of Kashi Amid Mahakumbh CelebrationsMaha Shivratri: CM Rekha Gupta Offers Prayers at Gauri Shankar Temple Amid Grand Mahakumbh CelebrationsMahakumbh: Grand Arrangements Praised by Foreign Devotees on Maha ShivratriMahakumbh: Final Holy Dip on Maha Shivratri, CM Yogi Monitors Arrangements from Control Room

Photo Gallery

Embed widget